16-Jan-2026
Xenon Pharmaceuticals Issues Inducement Stock Options to New Hires
TipRanks (Fri, 16-Jan 4:41 PM ET)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Jan 4:05 PM ET)
TipRanks (Tue, 13-Jan 2:35 PM ET)
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 12-Jan 8:30 AM ET)
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 8:30 AM ET)
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Globe Newswire (Fri, 5-Dec 9:00 AM ET)
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Globe Newswire (Wed, 3-Dec 8:30 AM ET)
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Globe Newswire (Tue, 25-Nov 8:30 AM ET)
Xenon to Present at Upcoming Investor Conferences
Globe Newswire (Thu, 6-Nov 8:30 AM ET)
Xenon Reports Third Quarter 2025 Financial Results & Business Update
Globe Newswire (Mon, 3-Nov 4:01 PM ET)
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.
As of January 16, 2026, XENE stock price declined to $39.98 with 930,314 million shares trading.
XENE has a beta of 0.85, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.12 to the broad based SPY ETF.
XENE has a market cap of $3.08 billion. This is considered a Mid Cap stock.
In the last 3 years, XENE traded as high as $50.99 and as low as $26.74.
The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, IWO, IBB, VTWO, SPDW.
XENE has underperformed the market in the last year with a price return of +0.9% while the SPY ETF gained +18.1%. XENE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.2% and -10.1%, respectively, while the SPY returned +5.0% and +1.2%, respectively.
XENE support price is $39.59 and resistance is $41.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.